ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
Argen X SE

Argen X SE (ARGX)

486,00
6,00
(1,25%)
Fermé 12 Octobre 5:30PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
486,00
Prix Achat
483,00
Prix Vente
487,00
Volume échangé
70 868
475,40 Fourchette du Jour 486,80
271,00 Plage de 52 semaines 502,40
Cap du marché
Clôture Veille
480,00
Ouverture
482,10
Dernière Transaction
56
@
486
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
60 273
Actions en circulation
59 194 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-105,45
Bénéfice par action (BPA)
-4,98
Chiffre d'affairess
1,27B
Bénéfice net
-295,05M

À propos de Argen X SE

Secteur
Coml Physical, Biologcl Resh
Industrie
Coml Physical, Biologcl Resh
Site Web
Siège social
Amsterdam, North Holland, Nld
Fondé
-
Argen X SE est coté dans le secteur Coml Physical, Biologcl Resh de la Euronext avec le ticker ARGX. Le dernier cours de clôture d'Argen X était de 480,00 €. Au cours de la dernière année, les actions de Argen X ont été négociées dans une fourchette de prix de 271,00 € à 502,40 €.

Argen X compte actuellement 59 194 000 actions en circulation. La capitalisation boursière d'Argen X est de 28,41 € milliard. Argen X a un ratio cours/bénéfice (ratio PE) de -105.45.

ARGX Dernières nouvelles

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced...

argenx to Present at Upcoming Investor Conferences

August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo following June 21st FDA approval On track to begin four additional registrational...

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in...

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development...

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases...

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

$398 million in first quarter global net product sales FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024 On track to submit filing for pre-filled syringe (PFS) in...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.6-0.532132623823488.6493.9470.350955479.19746166DE
400486502.4456.359635482.00164533DE
1260.614.245416079425.4502.4421.860273471.73693133DE
26129.636.3636363636356.4502.4323.459386417.46595309DE
5211.62.44519392917474.4502.427162558398.70546398DE
156231.490.8876669285254.6502.4224.165375358.93877522DE
260385.6384.06374502100.4502.493.0576790279.23476777DE

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ALRPDRapid Nutrition
0,0746 €
(28,18%)
15,67M
ALOKWGroupe Okwind SA
8,20 €
(17,14%)
15,15k
ALTHOMetavisio (Thomson Computing)
0,397 €
(16,42%)
1,34M
IBABIon Beam Applications SA
15,00 €
(14,16%)
178,95k
ALMEXMexedia SPA
6,80 €
(13,33%)
64
MLWEYWeya
0,02 €
(-95,45%)
10
ALAVEAventador
0,001 €
(-28,57%)
35,75M
ALDVAlliance Developpement Capital Siic
0,06 €
(-19,46%)
280,26k
GNROGeNeuro SA
0,0724 €
(-18,65%)
28,22k
MLGRCGroupe Carnivor
16,80 €
(-16,00%)
12
BCPBanco Comercial Portugues SA
0,4333 €
(3,51%)
141,92M
ALAVEAventador
0,001 €
(-28,57%)
35,75M
ALDOLDolfines
0,0006 €
(-14,29%)
29,46M
ALRPDRapid Nutrition
0,0746 €
(28,18%)
15,67M
ALNRGEnergisme SA
0,0061 €
(7,02%)
12,85M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock